IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
08.31.2020
Waltham, MA – August 31, 2020 – Asymchem, a leading global CDMO service provider, announced a strategic investment in Snapdragon Chemistry, a private U.S. chemical technology company focused on the design and development of efficient and sustainable manufacturing processes for pharmaceutical applications. Asymchem led the investment round, along with the participation from Snapdragon’s previous investors. The funding provides capital for Snapdragon to complete its expansion plan to build cGMP drug substance manufacturing suites.
“We are pleased to lead this investment round in Snapdragon to initiate our strategic collaboration,” said Dr. Hao Hong, CEO of Asymchem. “Asymchem’s strong technical capabilities and late-stage CDMO services, coupled with Snapdragon’s advanced flow chemistry technology and suite of CDO services, creates a synergistic partnership that will enable us to provide fully integrated CDMO services moving forward. We believe this funding will increase Snapdragon’s large pharmaceutical and biotech client base and allow us to transition clients from Snapdragon’s early-stage services to Asymchem for late-stage manufacturing and commercialization.”
Matt Bio, CEO of Snapdragon Chemistry, said “The combination of Snapdragon’s technology and process development capabilities, along with Asymchem’s expertise in clinical and commercial manufacturing will provide our clients with a complete solution to drug-development. The investment will also allow Snapdragon to accelerate the launch of a GMP manufacturing facility and continue to advance our technologies for process development.”
This investment is another milestone in Asymchem’s strategy of enhancing its integrated comprehensive service capability, improving its geographic footprint, and accelerating the delivery of an integrated service ecosphere for innovative medicines. As a CDMO service provider for over 20 years, Asymchem provides services to international and domestic markets and continuously expands its strategic reach.
About Snapdragon Chemistry Snapdragon Chemistry specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts, Snapdragon’s 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff. For more information, please contact info@snapdragonchemistry.com.
About Asymchem Asymchem (stock code: 002821.SZ) is a leading global integrated CDMO service provider of innovative drug R&D and manufacturing with 5000 employees based in P.R. China, U.S., and EU. We strive to drive efficiency through continuous technological advances for smarter, greener, and more cost-effective manufacturing to support pharmaceutical clinical research and commercialization backed by a proven track record of agency and industry inspections. For more information, please go to www.asymchem.com.